Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

The OS results were also related to PD-L1 status. For patients with a PD-L1 tumor proportion score (TPS) of less than 1%, the ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

Led by Dr. Rafael Bernardi from Auburn's Department of Physics and Dr. Michael Nash from the Department of Chemistry at the University of Basel, the study focuses on PD-L1, a protein that tumors use ...

This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

1 Notably, ~19% of the 21 patients in INSIGHT-003 with mature survival data have high PD-L1 expression, who typically respond better to anti-PD-1 therapy, versus ~32% in the registrational trial ...

INSIGHT-003 is biased towards low and negative PD-L1 (TPS 50%) patients who are typically less responsive to anti-PD-1 therapy. INSIGHT-003 is an investigator-initiated, multi-centre study led by the ...